GeorgeRichardThompson IIIMD

Infectious Disease • Sacramento, CA

Professor, University of California - Davis Medical Center

Join to view full profile

Dr. Thompson III is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Thompson III's full profile

Already have an account?

Office
4150 V St
Ste G500
Sacramento, CA 95817
Phone+1 916-734-3741

Fax+1 530-752-8692

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Infectious Disease, 2007 - 2009
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineChief Residency, Internal Medicine, 2006 - 2007
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 2004 - 2007
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineResidency, Internal Medicine, 2003 - 2006
University of Missouri-Columbia School of MedicineClass of 2003

Certifications & Licensure

CA State Medical License 2009 - 2027
TX State Medical License 2006 - 2009
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis Start of enrollment: 2007 Mar 07
COMPLETED
PHASE3
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections Start of enrollment: 2007 Mar 08
COMPLETED
PHASE3
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi Start of enrollment: 2008 Apr 22
COMPLETED
PHASE3
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
COMPLETED
PHASE2
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension Start of enrollment: 2016 Jul 26
Completed
Phase 2
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment Start of enrollment: 2017 Apr 01
COMPLETED
PHASE3
Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis Start of enrollment: 2021 Mar 16
Terminated
Phase 3
Olorofim Aspergillus Infection Study Start of enrollment: 2022 Mar 31
RECRUITING
PHASE3
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds Start of enrollment: 2020 Jan 04
Terminated
Phase 2
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. Start of enrollment: 2024 Dec 11
RECRUITING
PHASE3
Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections
Available
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole Start of enrollment: 2022 Aug 03
Suspended
Phase 3
Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis Start of enrollment: 2018 Oct 07
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Olorofim demonstratesactivity againstspecies, including isolates against which fluconazole has reduced activity.
Nathan P Wiederhold, Hoja P Patterson, Dora Ferrer, Victor Garcia, George R Thompson
Antimicrobial Agents and Chemotherapy. 2025-01-31
2 citations
Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised co...
Patrick M Honoré, Matteo Bassetti, Oliver A Cornely, Herve Dupont, Jesús Fortún
Critical Care. 2024-11-11
1 citations
Clinical Testing Guidance for Histoplasmosis in Patients With Community-acquired Pneumonia for Primary and Urgent Care Providers: Commentary on Enzyme Immunoassay Hist...
Dallas J Smith, George R Thompson 3rd, John W Baddley, Peter G Pappas, Lisa A Tushla
Clinical Infectious Diseases. 2024-09-26

Committees

President Elect, Mycoses Study Group 2024 - Present
Panelist, IDSA Journal Club 2009 - Present

Professional Memberships